What is the Value-Based HealthCare (VBHC) Outcomes Pledge Program?

The Value-Based HealthCare Outcomes Pledge Program is a collaborative and long-term partnership designed to address healthcare complications that result in poor outcomes and higher costs. This outcome-based partnership follows clinical protocols, clinician education, and targeted goals to help improve clinical outcomes.

We offer two program options:





Supported by clinically relevant metrics, the program options are structured to help improve clinical and economical outcomes. If you meet the program requirements but don’t reach targeted goals, you’ll receive a rebate.

Why Is Medtronic Offering this VBHC Outcomes Pledge Program?

Respiratory adverse events and ventilator-associated pneumonia impact patients’ outcomes1,2,3 and bring associated costs.1,2,4,5 We want to help you improve clinical outcomes and lower costs.

We believe the current healthcare system is not sustainable and needs to be transformed to control rising healthcare costs. We understand and support that healthcare system leaders around the world will implement value-based healthcare. This shift means that payment for our products and services may be contingent on how well our technologies improve patient outcomes and lower costs. We want to actively help lead this transformation.

This Value-Based HealthCare Outcomes Pledge Program isn’t a product performance guarantee. Rather, it was designed with the intent to foster a working partnership to improve clinical and financial outcomes in defined patient populations and support real-world evidence generation.

Furthermore, Medtronic will also benefit from the commercialization of the technologies associated with this program, including Microstream™ capnography, Shiley™ Evac Endotracheal Tube with TaperGuard™ Cuff,  and Shiley™ Automatic Cuff Controller. 

How Much Does this VBHC Outcomes Pledge Program Cost?

When organizations consider participating in our Value-Based HealthCare Outcomes Pledge Program, their first concern is usually cost.

In reality, the investment is meant to be cost-effective as your organization should be reducing costs by avoiding complications and improving clinical outcomes. Additionally, Medtronic will be sharing the financial risk with you by committing to support you if the outcomes are not achieved.

If you wish to receive detailed information on the necessary investment and cost benefits, contact your local sales representative.

Are You Sure This VBHC Outcomes Pledge Program Isn’t Too Good to Be True?

We believe that this program will improve patient outcomes and reduce costs. We expect this so strongly that we will pledge a substantial rebate if you meet the program requirement. Though we don’t jointly achieve the intended program targets.

We know you want to lower complication rates and improve outcomes in your facility. And you may not have the time or resources to figure out how. That’s where we can help.

The Value-Based HealthCare Outcomes Pledge Program requires a commitment from both of us to succeed. What do we ask from you?

  • Establish a clinical protocol
  • Agree to share data with us
  • Participate in quarterly reviews
  • Ensure that participating staff members complete the required training and education.

In return, we shall support you in all these activities.

  • 1. Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med. 2005 Oct;33(10):2184-93. doi: 10.1097/01.ccm.0000181731.53912.d9. PMID: 16215368.

  • 2. Torres A, Niederman MS, Chastre J, Ewig S, Fernandez-Vandellos P, Hanberger H, Kollef M, Li Bassi G, Luna CM, Martin-Loeches I, Paiva JA, Read RC, Rigau D, Timsit JF, Welte T, Wunderink R. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J. 2017 Sep 10;50(3):1700582. doi: 10.1183/13993003.00582-2017. PMID: 28890434.

  • 3. Koulenti D, Tsigou E, Rello J. Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study. Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):1999-2006. doi: 10.1007/s10096-016-2703-z. Epub 2016 Jun 10. PMID: 27287765.

  • 4. Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm L, Redman R, Kollef MH; VAP Outcomes Scientific Advisory Group. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest. 2002 Dec;122(6):2115-21. doi: 10.1378/chest.122.6.2115. PMID: 12475855.

  • 5. Kollef MH, Hamilton CW, Ernst FR. Economic impact of ventilator-associated pneumonia in a large matched cohort. Infect Control Hosp Epidemiol. 2012 Mar;33(3):250-6. doi: 10.1086/664049. Epub 2012 Jan 17. PMID: 22314062.